Absorption

Velan Inc. Reports Solid Third Quarter 2022/23 Financial Results, With an Improving Trend in Backlog, Revenues and Profit

Retrieved on: 
Wednesday, January 11, 2023
Administration, Absorption, Movement, EBITDA, Translation, EST, CEWS, COVID-19, Drug, Film, Video game, Fossil fuel, Pharmaceutical industry

Bookings2 for the quarter amounted to $99.2 million, an increase of $10.7 million or 12.1% compared to the third quarter of last year.

Key Points: 
  • Bookings2 for the quarter amounted to $99.2 million, an increase of $10.7 million or 12.1% compared to the third quarter of last year.
  • The decrease for the nine-month period was partially offset by a strong bookings2 quarter from the Company’s North American operations which recorded significant marine orders.
  • Sales amounted to $95.2 million for the quarter, decreasing by $14.7 million or 13.4% compared to the same quarter last year.
  • Gross profit for the quarter amounted to $29.0 million, a decrease of $6.9 million or 19.2% compared to the same quarter last year.

Polycarbonate Films Global Market Report 2022: Growing Adoption of Polycarbonate Films as an Alternative to Conventional Material Boosts Sector - ResearchAndMarkets.com

Retrieved on: 
Monday, January 9, 2023
Chemicals, Plastics, Manufacturing, Carbon, UV, DKSH, SWM, Metal, Heat, BPA, Double-Function Form, PLUS, Absorption, Certification, Glass, Polyetherimide, Competition, Multi, Mitsui Chemicals, Car, Health, ID, Electronics, Atmosphere, Hardness, Air conditioning, Optics, Biomass, International Sustainability Alliance, SABIC, ISCC, Wood, Video game, Chemical, Thermoplastic, Teijin, Weathering steel

By 2028, the global market for Polycarbonate Films is expected to grow impressively due to increasing demand from the automobile sector.

Key Points: 
  • By 2028, the global market for Polycarbonate Films is expected to grow impressively due to increasing demand from the automobile sector.
  • Polycarbonate films are becoming increasingly popular due to their superior dielectric strength, reduced moisture absorption, and good dimensional stability.
  • Moreover, biomass-based polycarbonate film gets more preference as it is made from bio-BPA, boosting the polycarbonate films market.
  • In this report, global polycarbonate films market has been segmented into the following categories, in addition to the industry trends, which have also been detailed below:

Global Biophotonics Market Report 2022 to 2027: Industry Trends, Share, Size, Growth, Opportunities and Forecasts

Retrieved on: 
Tuesday, January 10, 2023
Agriculture, Organic acid, Environmental science, Dentistry, Thermo Fisher Scientific, Environmental monitoring, Protein, Carl-Zeiss-Stiftung, Research, Carl Zeiss AG, COVID-19, Virus, Oxford, Microscopy, R, Becton, Absorption, Patient, PerkinElmer, Gold, Medicine, PAT, Becton, Dickinson and Company headquarters, Investment, Olympus Corporation, Biophotonics, Nanotechnology, Prevalence, Cell, Google Images, Renewable energy, Medical imaging, Vaccine, Potash, Growth

DUBLIN, Jan. 10, 2023 /PRNewswire/ -- The "Biophotonics Market: Global Industry Trends, Share, Size, Growth, Opportunity and Forecast 2022-2027" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • DUBLIN, Jan. 10, 2023 /PRNewswire/ -- The "Biophotonics Market: Global Industry Trends, Share, Size, Growth, Opportunity and Forecast 2022-2027" report has been added to ResearchAndMarkets.com's offering.
  • The global biophotonics market size reached US$ 44.8 Billion in 2021.
  • What has been the impact of COVID-19 on the global biophotonics market?
  • What is the structure of the global biophotonics market and who are the key players?

CACAYE, a New Line of High-Performance Skincare Rooted in the Power of Nature Launches in the US

Retrieved on: 
Monday, January 9, 2023
Cancer, Innovation, Friends, Pedigree, Procter & Gamble, Beauty, Greasy, Skin, Vitamin, Dehydration, Irritation, Elasticity, Chanel, Absorption, Family, Xanthosoma, Nature, Nutrient, Organic acid, Heart, Ageing, Fermentation, Amazon, Collection, Woman, Cosmetics, TikTok

NEW YORK, Jan. 9, 2023 /PRNewswire/ -- CACAYE, the premiere product offering conceived by Evoq Brand Lab, introduces a new efficacious skincare collection sitting at the intersection of superior ingredients and innovative science. At the heart of all CACAYE products is CaCay – a precious nut oil native to the Amazon that is rich in essential fatty acids and vitamins, making it a true skincare powerhouse and cure-all. Applied daily, CaCay Oil has a variety of benefits including components that improve the appearance of lines, wrinkles, tone, dehydration, dark spots, irritation, and sensitivity without an oily or sticky finish.

Key Points: 
  • "CACAYE represents our vision for the future of skincare – a union of breakthrough formulation techniques and deep knowledge of the world's botanicals," Karl Obrecht, Evoq Brand Lab, CEO.
  • "Through our revolutionary approach and by realizing the full potential of each ingredient, CACAYE offers maximum results rooted in the power of nature, which we are excited to bring to the skincare consumer."
  • Each product has been thoughtfully formulated for all skin types, tones, and textures at every stage of maturity.
  • Through active ingredients and technical formulas, CACAYE offers clinically proven skincare solutions to support the skin's natural abilities and revitalize the complexion.

AdValue Photonics Introduces 308 nm Single Frequency Fiber Laser

Retrieved on: 
Monday, January 9, 2023
Halogen, Laser, Electronics, Photonics, Multimedia, Absorption, Safety, Light, Goddard Space Flight Center, Xenon monochloride, DUV, Dermatology, LIDAR, Microscope, Laser construction

AdValue Photonics 308 nm single frequency laser is the first of its kind, all solid state version to emit 3 W average power with a diffraction limited beam.

Key Points: 
  • AdValue Photonics 308 nm single frequency laser is the first of its kind, all solid state version to emit 3 W average power with a diffraction limited beam.
  • "The fiber-based 308 nm laser is an inflection point for real world laser applications, since previous technology required toxic chemical lasers to generate high power at this wavelength," said Dr. Michael Mielke, AdValue Photonics CEO.
  • AdValue Photonics is in development of higher power versions of the 308 nm laser in form factors specific to medical and remote sensing applications.
  • AdValue Photonics' focused portfolio of fiber laser technology includes infrared, visible, and now UV lasers with peak performance beyond the traditional limits.

Landos Biopharma Provides Comprehensive Update on Clinical Development Plans

Retrieved on: 
Thursday, January 5, 2023
Johns Hopkins School of Medicine, Clinical trial, Diabetic nephropathy, Diabetes, Ulcerative colitis, Steroid, Partnering, Multiple sclerosis, LANCL2, Telephone number (mathematics), MS, Research, Non-alcoholic fatty liver disease, Lupus, Eosinophilic esophagitis, NASH, Psoriasis, Atopic dermatitis, Neurology, Moa, NLRX1, Alzheimer's disease, Disease, Gastroenterology, Rheumatoid arthritis, CNS, Absorption, Patient, Chronic obstructive pulmonary disease, Degenerative disease, RA, Safety, Foundation for the National Institutes of Health, Webcast, SLE, Conference, UC, Race, Endoscopy, International, Pharmaceutical industry, Vaccine, MD, Asthma

Broader, Novel Pipeline Poised for Partnering and Continued Development in the Future;

Key Points: 
  • Broader, Novel Pipeline Poised for Partnering and Continued Development in the Future;
    NEW YORK, Jan. 05, 2023 (GLOBE NEWSWIRE) -- Landos Biopharma, Inc. (NASDAQ: LABP) (“Landos” or the “Company”), a clinical-stage biopharmaceutical company developing novel, oral medicines for patients with autoimmune diseases, today announced a comprehensive update on its future clinical development plans.
  • “After thorough analysis and careful consideration, we are confident that focusing our resources toward NX-13’s clinical development has the potential to deliver the most value for Landos and our shareholders,” said Gregory Oakes, President and Chief Executive Officer of Landos.
  • “Our goal is to evolve Landos from a discovery-based organization into an immunology development powerhouse.
  • The Company will host a live webcast to provide a comprehensive update on Landos’ clinical development plans at 8:00 AM ET today.

Richardson Electronics Reports Second Quarter Fiscal 2023 Net Income of $5.5 Million or 8.4% of Net Sales; Declares Quarterly Cash Dividend

Retrieved on: 
Wednesday, January 4, 2023
Electronics, Public expenditure, RF, FINANCIAL, Travel, Growth, Absorption, CT, Investment, Microwave, GES, Central Time, NOLS, PMT, Sintering, Video game, Health insurance, Security (finance), Taula de canvi, Health care

LAFOX, Ill., Jan. 04, 2023 (GLOBE NEWSWIRE) -- Richardson Electronics, Ltd. (NASDAQ: RELL) today reported financial results for its second quarter ended November 26, 2022. The Company also announced that its Board of Directors declared a $0.06 per share quarterly cash dividend.

Key Points: 
  • Backlog totaled $192.6 million in the second quarter versus $199.2 million at the end of the first quarter of fiscal 2023 and $146.9 million at the end of the second quarter of last fiscal year.
  • Operating income was $7.2 million in the second quarter of fiscal 2023 compared to $4.5 million for the second quarter of fiscal 2022.
  • Gross margin was 33.2% of net sales during the second quarter of fiscal 2023 compared to 32.7% of net sales during the second quarter of fiscal 2022.
  • Net income for the second quarter of fiscal 2023 was $5.5 million compared to net income of $4.1 million in the second quarter of fiscal 2022.

Healthy Extracts’ Whitney Johns Brain Activate ENERGY Gel Packs Now Available on Amazon.com

Retrieved on: 
Wednesday, December 21, 2022
The Non-GMO Project, C8, Amazon (company), OTCQB, BRAIN, Memory, Brain, Digestion, Sport, Woman, Absorption, Attention, Learning, Nutrient, Ultimate Brain, Heart, Sugar, Health, Caffeine, Top 10 Hits of the End of the World, Cognition, EEG, Lutein, Amazon, Marketing, Energy gel, Pharmaceutical industry, Medical imaging, Mobile phone

The concentrated natural gel formulation provides the perfect “brain food” for sustained mental energy and attention without added sugars.

Key Points: 
  • The concentrated natural gel formulation provides the perfect “brain food” for sustained mental energy and attention without added sugars.
  • Whitney Johns Nutrition products are the first private-label formulations developed and launched through Healthy Extracts’ innovative brand influencer program .
  • Whitney Johns Brain Activate – ENERGY Gel is specially formulated to support focus, memory, cognition, mood and brain health, as well as reduce brain fog and support natural sleep patterns.
  • Whitney Johns line of brain, physical performance and women’s hormone health products are based upon Healthy Extracts’ all-natural Citrus Bergamot SuperFruit™ and Ultimate Brain Nutrients™ formulations.

Hemp, Inc. Reports: Industrial Hemp Unlocks New Revenue Sources as the New Year Approaches

Retrieved on: 
Tuesday, December 20, 2022
Textile, CBN, Housing and Urban Development Corporation, Senate, Empire State Development Corporation, Growth, Absorption, Commissioner, CBD, CBDA, OTC, Agricultural Marketing Service, Building material, CBGA, Seed, CBG, Agriculture, Pulp (paper), Hemp, Research

As another report eloquently stated, “Industrial hemp is a cultivar of the plant Cannabis sativa (marijuana) that is utilized for a range of industrial and personal purposes.

Key Points: 
  • As another report eloquently stated, “Industrial hemp is a cultivar of the plant Cannabis sativa (marijuana) that is utilized for a range of industrial and personal purposes.
  • Hemp fiber, hemp oil, and hemp seeds are some of hemp’s by-products.
  • As one of the pioneers in the hemp industry, Hemp, Inc.’s foothold runs 14 years deep.
  • The Company has facilities on the east and west coast and offers the broadest range of industrial hemp products.

Exelixis Announces Preliminary Fourth Quarter and Full Year 2022 Financial Results, Provides 2023 Financial Guidance, and Outlines Key Priorities and Milestones for 2023

Retrieved on: 
Sunday, January 8, 2023
Oncology, Health, Genetics, Clinical Trials, Pharmaceutical, Biotechnology, Cancer, District court, Colorectal cancer, Growth, Large-cell lung carcinoma, Renal cell carcinoma, Catalent, Roche, Nivolumab, Calendar, Therapeutic index, Arm, Head, 5T4, FDA, Antibody, IO, Neck, DC, SIRP, ANDA, Prostate, CD47, Absorption, Ipilimumab, Safety, Webcast, Control, Software, Investigational New Drug, Thyroid cancer, Pharmacokinetics, RCC, Survival analysis, News, Biomarker, CDK7, Breast, Patient, CRC, Tumor microenvironment, ADC, Allele, Conference, Pivotal, Liver, Health insurance, Insurance, Pharmaceutical industry, Vaccine, Exelixis, IND

The preliminary 2022 financial information presented in this press release has not been audited and is subject to change.

Key Points: 
  • The preliminary 2022 financial information presented in this press release has not been audited and is subject to change.
  • The complete Exelixis Fourth Quarter and Full Year 2022 Financial Results are planned for release after market on Tuesday, February 7, 2023.
  • Exelixis President and Chief Executive Officer Michael M. Morrissey, Ph.D., will provide a corporate overview and discuss the company’s preliminary fourth quarter and full year 2022 financial results, 2023 financial guidance, and key priorities and milestones for 2023 during the company’s presentation at the J.P. Morgan Healthcare Conference beginning at 8:15 p.m.
  • To access the webcast link, log onto www.exelixis.com and proceed to the News & Events / Event Calendar page under the Investors & Media heading.